Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Helix BioPharma Corp.TSX: HBP.TO
Accumulated OCI · Q3 FY2026 · quarter ended Apr 2026
Accumulated OCI falls 29.9% from a year ago
Accumulated OCI stood at CA$2.7M at the end of Q3 FY2026, down 29.9% from a year earlier and down 30.3% from the prior quarter. Over 3 fiscal years it compounded at -27.9% a year.
Context
- Accumulated OCI amounted to 12.6% of total assets at the end of Q3 FY2026, down 369.0 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -29.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
CAD · from the balance sheet
- Latest · FY2025
- 3.87M CAD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -33.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 3.87M | -16.7% |
| FY2024 | 2024-07-31 | 4.65M | +6.7% |
| FY2023 | 2023-07-31 | 4.36M | -57.8% |
| FY2022 | 2022-07-31 | 10.34M | -47.4% |
| FY2021 | 2021-07-31 | 19.63M | — |
Accumulated OCI vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -29.9% is the lowest of 3, against a peer median of +633.3%.
- Accumulated OCI amounts to 12.6% of total assets for HBP.TO, versus a peer median of 16.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $17.64M USD | +1244.5% | +133.1% | 23.4% |
| Mar 2026 | CA$2.82M CAD | — | — | 9.0% | |
| Apr 2026 | CA$2.7M CAD | -29.9% | -27.9% | 12.6% | |
| Apr 2026 | CA$1.74M CAD | — | -45.4% | 113.6% | |
| Mar 2026 | -$7.72M USD | +22.0% | — | 5.9% | |
| Peer median (excluding HBP.TO) | — | +633.3% | +43.8% | 16.2% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.